IDEAYA Biosciences, Inc..
IDYA.US | Research and experimental development on natural sciences and engineering
IDEAYA Biosciences, Inc. is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. They focus on areas of unmet medical need, particularly in cancers with defined genetic or biological dr...Show More
Better Health for All
-20
IDEAYA Biosciences is a precision medicine oncology company entirely focused on the discovery and development of transformative therapies for cancer, aiming to improve clinical outcomes for patients. Its investigational drug, darovasertib, demonstrated a median overall survival of 21.1 months in a Phase 2 trial for metastatic uveal melanoma, significantly exceeding the historical median of approximately 12 months.
1
The company has no products with significant negative health impacts. The darovasertib and crizotinib combination therapy observed a low rate of 10% drug-related serious adverse events and predominantly Grade 1 or 2 drug-related adverse events, with no Grade 4 or 5 drug-related adverse events reported for IDE161.
2
The company's Director of Patient Support Services is tasked with ensuring every eligible patient can access, afford, and remain adherent to darovasertib, managing out-of-pocket assistance and patient assistance programs.
3
IDEAYA's trials include both HLA*A2:01-negative and HLA*A2:01-positive patients, and the proportion of patients with ECOG PS 1 in the OptimUM-01 study was approximately two times higher than an earlier published registrational study in mUM.
4
The company's press releases contain forward-looking statements that involve substantial risks and uncertainties, with further descriptions of risks in its Annual Report on Form 10-K.
5
IDEAYA and Servier will collaborate on development costs and target a global Phase 3 randomized clinical trial in 2026 to evaluate adjuvant darovasertib in primary UM, including both HLA-A2-negative and -positive patients.
6
The company offers a competitive total rewards package including 100% company-paid medical/dental/vision coverage for employees and 90% for dependents.
7
The company's comprehensive benefits package includes wellness programs.
8
IDEAYA is subject to numerous federal, state, and foreign laws governing health data protection and has established physical, electronic, and organizational measures to safeguard its systems.
9
The company acknowledges that public health outbreaks may adversely affect its operations.
10
IDEAYA conducts clinical trials under GCP regulations, requiring informed consent and IRB review and approval for each protocol and consent form.
11
Fair Money & Economic Opportunity
0
No evidence available to assess IDEAYA Biosciences, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess IDEAYA Biosciences, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No quantitative data was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The articles primarily consist of the company's Code of Business Conduct and Ethics, overviews of its research and development, or general industry information.
1
One article referred to a different company, IDEMIA, and was therefore not relevant.
2
None of the articles contain specific metrics on fair trade certifications, audit frequency, forced/child labor incidents, traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend.
Honest & Fair Business
0
No evidence available to assess IDEAYA Biosciences, Inc. on Honest & Fair Business.
Kind to Animals
0
No relevant data was found in the provided articles to assess IDYA.US against the 'Kind to Animals' ethical value. All articles explicitly state that they contain no quantitative data, regulatory actions, certifications, or other specific information pertaining to the company's animal welfare practices.
1
No War, No Weapons
0
IDEAYA Biosciences is a precision medicine oncology company focused on developing targeted therapeutics for cancer.
1
The provided articles consistently describe its core business as entirely dedicated to oncology research and development. There is no evidence of any revenue derived from arms or defense contracts, involvement in dual-use technologies with military applications, exposure to controversial weapons, or any defense-related assets that would require divestment.
2
Therefore, these activities are not applicable to the company's core business model.
Planet-Friendly Business
0
The provided articles do not contain specific, concrete data points for any of the Planet-Friendly Business KPIs. While an ESG Risk Score of 38
1
or 38.4
2
is mentioned, this is a general risk rating and does not map to any of the quantitative environmental metrics required by the rubric, such as emissions, renewable energy use, water consumption, or waste diversion. The articles explicitly state that relevant ESG data is not available or not provided.
3
4
5
Therefore, no KPIs can be scored based on the available evidence.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles to assess IDEAYA Biosciences, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles focus on a job posting
1
and the company's research and development in precision medicine oncology
2
, without providing information on community engagement, cultural impact, local investment, or related metrics.
Safe & Smart Tech
0
No evidence available to assess IDEAYA Biosciences, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Zero Waste & Sustainable Products. The articles either explicitly state a lack of data for these metrics or provide general ESG risk ratings without quantitative details on waste management, product sustainability, or related initiatives. A general 'negative impact' score for 'Waste' was noted, but it lacks the specific quantitative data required by the rubric's KPIs.
1